Response to antiseizure medications in neonates with acute symptomatic seizures.

Glass, Hannah C;Soul, Janet S;Chu, Catherine J;Massey, Shavonne L;Neonatal Seizure Registry study group;et.al.
(2019) Epilepsia — Vol. 60, n° 3, p. e20-e24 (2019)

Files

2019_Glass_Epilepsia_Postprint.pdf
  • Open Access
  • Adobe PDF
  • 420.84 KB
Download

Details

Authors
  • Glass, Hannah Corcid-logo
    Author
  • Soul, Janet S
    Author
  • Chu, Catherine J
    Author
  • Massey, Shavonne L
    Author
  • Cilio, Maria-RobertaUCLouvain
    Author
  • Neonatal Seizure Registry study group
    Collaborator
Show more
Abstract
In a prospective cohort of 534 neonates with acute symptomatic seizures, 66% had incomplete response to the initial loading dose of antiseizure medication (ASM). Treatment response did not differ by gestational age, sex, medication, or dose. The risk of incomplete response was highest for seizures due to intracranial hemorrhage and lowest for hypoxic-ischemic encephalopathy, although the difference was not significant after adjusting for high seizure burden and therapeutic hypothermia treatment. Future trial design may test ASMs in neonates with all acute symptomatic seizure etiologies and could target neonates with seizures refractory to an initial ASM.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Glass, H. C., Soul, J. S., Chu, C. J., Massey, S. L., Wusthoff, C. J., Chang, T., Cilio, M.-R., Bonifacio, S. L., Abend, N. S., Thomas, C., Lemmon, M., McCulloch, C. E., & Shellhaas, R. A. (2019). Response to antiseizure medications in neonates with acute symptomatic seizures. Epilepsia, 60(3), e20-e24. https://doi.org/10.1111/epi.14671 (Original work published 2019)